Cancer Advisor

Executive Summary Cancer immunotherapy represents one of the most consequential paradigm shifts in oncology since the advent of combination chemotherapy [1–3]. By targeting immune checkpoints, tumor antigens, or immune effector cells themselves, immunotherapies have delivered durable, and in some cases curative, responses in a subset of patients across historically lethal malignancies [4–7]. However, population-level benefit remains heterogeneous. Immune checkpoint inhibitors (ICIs) consistently extend survival in several cancers, although absolute overall survival (OS) gains are often modest at a population level . Many regulatory approvals rely on surrogate endpoints rather than mature overall survival (OS) data [32,35], immune-related toxicities can be severe or permanent [28–30], and costs place substantial strain on healthcare systems [38–40]. Real-world effectiveness frequently diverges from pivotal trial results [54]. Credit:  Statista 1. Introduction 1.1 Historical Context...

Authors:  Ilyes Baghli 1 , William Makis 2 , Paul E. Marik 3 , Michael J. Gonzalez 4,5,6 , William B. Grant 7 , Ron Hunninghake 8 , Thomas E. Levy 8 , Homer Lim 9 , Richard Z. Cheng 10 , Igor Bondarenko 11 , Paul Bousquet 12 , Roberto Ortiz 13 , Mignonne Mary 14 , Dominic P. D’Agostino 15 , Pierrick Martinez 16 1  International Society for Orthomolecular Medicine, Toronto, ON, Canada 2  Alberta Health Services, Cross Cancer Institute, Edmonton, AB, Canada 3  Frontline COVID-19 Critical Care Alliance, Washington, DC, USA 4  University of Puerto Rico, Medical Sciences Campus, School of Public Health, San Juan, PR 5  Universidad Central del Caribe, School of Chiropractic, Bayamon, Puerto Rico 6  EDP University, Naturopathic Sciences Program, Hato Rey, Puerto Rico 7  Sunlight, Nutrition, and Health Research Center, San Francisco, CA, USA 8  Riordan Clinic, 3100 North Hillside, Wichita, KS, USA 9  Akesis Holistic Health, Manila, Philippines 1...

William Makis; Ilyes Baghli; Pierrick Martinez (Corresponding Author) Case Rep Oncol (2025) 18 (1): 856–863. https://doi.org/10.1159/000546362 PubMed: 40605964 Abstract Background:  Fenbendazole (FBZ), an inexpensive and widely accessible antiparasitic drug used in veterinary medicine, has garnered growing interest for its potential as an anticancer therapy. Preclinical studies suggest that FBZ exerts its anticancer effects through a wide variety of mechanisms. While FBZ has shown promise both in vitro and in vivo studies, clinical evidence supporting its use and efficacy in treating metastatic cancer is currently limited.  Case Presentations:  This report highlights 3 cases of patients with advanced cancer – including breast, prostate, and melanoma. Two patients achieved complete remission, and one achieved near-complete remission after inco...